Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Angelo M. De Marzo"'
Autor:
Samuel R. Denmeade, Laura A. Sena, Jun Luo, Mark C. Markowski, Angelo M. De Marzo, Sushant Kachhap, Emmanuel S. Antonarakis
Publikováno v:
Clin Genitourin Cancer
Bipolar androgen therapy (BAT) is a novel treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively identified patients with mCRPC that achieved deep PSA responses to BAT. All patients with avail
Autor:
Erickson A, Carlos S. Moreno, Michelle M. Kouspou, Fred Saad, Michael S. Lewis, Onur Ertunc, Adeboye O. Osunkoya, Colm Morrissey, Bigler Sa, Tuomas Mirtti, Anne-Marie Mes-Masson, Stephen J. Freedland, Zhou X, Igor Vidal, Aud Svindland, Larry True, Tracy Jones, Ouellet, Mark Buzza, Wiley K, Tasken Ka, Pekka Taimen, Isla P. Garraway, Ariel H Achtman, Bova Sg, Angelo M. De Marzo, Bruce J. Trock, Dominique Trudel, Berge, Tarja Lamminen, Beatrice S. Knudsen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:715-727
Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Pl
Autor:
Srinivasan Yegnasubramanian, Jonathan W. Simons, William G. Nelson, Michael C. Haffner, Andries M. Bergman, Lodewyk F. A. Wessels, Tesa M. Severson, Matthew L. Freedman, Wilbert Zwart, Tracy Jones, Yanyun Zhu, Angelo M. De Marzo
Publikováno v:
Molecular Oncology, Vol 15, Iss 7, Pp 1942-1955 (2021)
Molecular Oncology
Molecular Oncology, 15(7), 1942-1955. Elsevier
Molecular Oncology
Molecular Oncology, 15(7), 1942-1955. Elsevier
The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly understood. We studied the epigenomic landscape of prostate cancer drivers using transcriptional profiling and ChIP‐seq in four clonal metastatic tumors d
Autor:
Lorelei A. Mucci, Alan K. Meeker, Edward Giovannucci, Meir J. Stampfer, Reza Zarinshenas, Angelo M. De Marzo, Elizabeth A. Platz, Misop Han, Tamara L. Lotan, Christine Davis, Corinne E. Joshu, Jiayun Lu, John R. Barber, Christopher M. Heaphy
Publikováno v:
The journal of pathology. Clinical research. 8(5)
PurposeCurrent biomarkers are inadequate prognostic predictors in localized prostate cancer making treatment decision-making challenging. Previously, we observed that the combination of more variable telomere length among prostate cancer cells and sh
Autor:
Zhongyuan Zhang, W. Nathaniel Brennen, Angelo M. De Marzo, Alexandria Brame, Levent Trabzonlu, Sarah R. Amend, Denis Wirtz, Timothy E. G. Krueger, Ashley Kiemen, Amber E. de Groot, Kayla V. Myers, Kenneth J. Pienta, Vicente E Torres, Natalia H Nagy
Publikováno v:
Prostate
Background Tumor-associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect the complete TME of a human patient or the natural initiation and
Autor:
William G. Nelson, Phyllis J. Goodman, Susan Chadid, Xiaoling Song, Bora Gurel, Scott M. Lippman, Ian M. Thompson, Howard L. Parnes, Elizabeth A. Platz, Jeannette M. Schenk, M. Scott Lucia, Marian L. Neuhouser, Angelo M. De Marzo
Publikováno v:
Nutr Cancer
Non-supplemental carotenoids and retinol may potentiate antioxidant and anti-inflammatory mechanisms. Chronic intraprostatic inflammation is linked to prostate carcinogenesis. We investigated the association of circulating carotenoids and retinol wit
Autor:
William G. Nelson, Jonathan I. Epstein, Martine Roudier, Michael C. Haffner, Srinivasan Yegnasubramanian, Lawrence D. True, Peter S. Nelson, Wilbert Zwart, Angelo M. De Marzo
Publikováno v:
Nat Rev Urol
From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous disease. Primary prostate cancers are often multifocal, having topographically and morphologically distinct tumour foci. Sequencing studies have revealed tha
Autor:
Mohammed Alshalalfa, Peter A. Sims, Ilsa Coleman, Jaime Yeji Kim, Angelo M. De Marzo, Onur Ertunc, Junfei Zhao, Renu K. Virk, Felix Y. Feng, Min Zou, Antonina Mitrofanova, Jun Luo, Antonio Rodriguez, Cory Abate-Shen, R. Jeffrey Karnes, Julia Fountain, Hanina Hibshoosh, Juan Arriaga, Sukanya Panja, Peter S. Nelson, Raul Rabadan, Emmanuel S. Antonarakis, Arianna Giacobbe, Busra Ozbek, Chioma J. Madubata, Mark A. Rubin
Publikováno v:
Nat Cancer
Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that NPKEYFP mice (for Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+)
Autor:
William G. Nelson, Michael T. Marrone, Berrak Gumuskaya, Charles G. Drake, Fan Pan, Ian M. Thompson, Ibrahim Kulac, Jun O. Liu, Phyllis J. Goodman, Ines Benedetti, Lauren M. Hurwitz, M. Scott Lucia, Elizabeth A. Platz, Angelo M. De Marzo, Catherine M. Tangen, Javier A. Baena Del Valle, William B. Isaacs, Kathryn B. Arnold
Publikováno v:
Cancer Prev Res (Phila)
Aspirin and statin use may lower the risk of advanced/fatal prostate cancer, possibly by reducing intraprostatic inflammation. To test this hypothesis, we investigated the association of aspirin and statin use with the presence and extent of intrapro
Autor:
Susan L. Dalrymple, Yezi Zhu, Peter S. Nelson, Jun Luo, Jianfeng Xu, Alan K. Meeker, Samuel R. Denmeade, Emmanuel S. Antonarakis, S. Lilly Zheng, William B. Isaacs, Angelo M. De Marzo, Jody E. Hooper, Ilsa Coleman, John T. Isaacs, W. Nathaniel Brennen
Publikováno v:
Oncogene
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi)